In a xenograft model (Zhou R. et al., 2019), CAR T cells modified by TAB004, a monoclonal antibody that is highly specific for the tumor-associated mucin1 glycoprotein (MUC1), was capable to increase the production of Granzyme B, IFN-γ, and other Th1 type cytokines, chemokines and significantly reduced the progression of tumor-associated MUC1 positive TNBC. This evidence concerns the gene GZMB and neoplasm.